Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 111(2024), 2 vom: 09. Feb., Seite 130-132 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Pembrolizumab en association au trastuzumab plus chimiothérapie dans les cancers gastriques et de la jonction œsogastrique localement avancés ou métastatiques HER2 surexprimés et CPS≥1 |
|---|
| Beteiligte Personen: |
Lévêque, Inès [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2023.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365619264 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365619264 | ||
| 003 | DE-627 | ||
| 005 | 20240214233001.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2023.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM365619264 | ||
| 035 | |a (NLM)38071114 | ||
| 035 | |a (PII)S0007-4551(23)00439-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lévêque, Inès |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1 |
| 246 | 3 | 3 | |a Pembrolizumab en association au trastuzumab plus chimiothérapie dans les cancers gastriques et de la jonction œsogastrique localement avancés ou métastatiques HER2 surexprimés et CPS≥1 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Spitzer, Eléonore |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 111(2024), 2 vom: 09. Feb., Seite 130-132 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2024 |g number:2 |g day:09 |g month:02 |g pages:130-132 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2023.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2024 |e 2 |b 09 |c 02 |h 130-132 | ||